Progress in targeting the untouchables: emerging approaches for hard-to-drug cancer targets

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Meaningful innovation in drug development is shifting towards targeting historically 'untouchable' proteins.
• Transcription factors, tumor suppressors, and lineage-defining proteins have long resisted conventional drug development.

Purpose of the Study:

• To review key highlights from the ESMO Targeted Anticancer Therapies (TAT) 2025 Congress and other drug development meetings.
• To explore novel therapeutic strategies and modalities for targeting previously inaccessible cancer targets.
• To present early-phase data on compelling compounds and trials for 'untouchable' targets.

Main Methods:

• Review of presentations and data from the ESMO TAT 2025 Congress and other pivotal drug development meetings.
• Analysis of early-phase clinical trial data for novel anticancer agents.
• Categorization of targets (KRAS, MYC, TP53, WNT) and modalities (PROTACs, ADCs, bispecifics).

Main Results:

• Early-phase trials are testing and refining novel modalities for targeting 'untouchable' proteins.
• First-in-human studies showcase the feasibility of drugging historically inaccessible sites.
• Data from compelling trials and compounds demonstrate progress beyond proof-of-concept.

Conclusions:

• Translational frameworks, rational trial design, and platform-specific engineering are expanding the scope of druggable targets.
• Novel modalities like PROTACs, ADCs, and bispecifics are crucial for targeting previously inaccessible proteins.
• Further research is needed to translate early successes into clinically meaningful benefits for cancer patients.